Regeneron Pharmaceuticals Delivers 19% Revenue Growth
Regeneron Pharmaceuticals reported a 19% revenue growth in Q1 2026, driven by strong sales of Dupixent and Eylea HD. The company beat quarterly estimates, but shares fell on weakness in Eylea demand. Regeneron also announced a $3 billion buyback and has its first gene therapy approval.
Regeneron Pharmaceuticals delivered a strong Q1 2026 earnings report, with 19% revenue growth driven by robust sales of Dupixent and Eylea HD. The company's Dupixent medication drove significant revenue growth and beat quarterly estimates. However, shares fell in response to weakness in Eylea demand, as observed in recent quarterly earnings.
Despite this, Regeneron secured its first gene therapy approval, marking a milestone for the company. The approval comes on the heels of a strong quarterly performance and highlights Regeneron's commitment to innovation and growth.
In addition to reporting strong earnings, Regeneron announced a $3 billion buyback program, returning capital to shareholders and positioning the company for long-term success.
Related Stocks
Powered by SentiSense - Intelligent Market Analysis